I simply updated the price & royalties in the Karst Peak
valuation (and used a 50% drug price discount for RoW),
and the model suggests $32 valuation today. Only $200m placeholder for NNZ.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-4548
-
- There are more pages in this discussion • 6,324 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.26 |
Change
0.810(3.96%) |
Mkt cap ! $2.716B |
Open | High | Low | Value | Volume |
$20.56 | $21.55 | $20.54 | $4.445M | 210.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 83 | $21.26 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.27 | 53 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 21.260 |
5 | 1105 | 21.250 |
8 | 383 | 21.240 |
2 | 159 | 21.230 |
2 | 160 | 21.220 |
Price($) | Vol. | No. |
---|---|---|
21.280 | 262 | 2 |
21.290 | 257 | 4 |
21.300 | 572 | 4 |
21.310 | 5126 | 5 |
21.320 | 222 | 3 |
Last trade - 12.27pm 16/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, CEO / Non-Exec Director
James Graham / Dr Alan Dunton
CEO / Non-Exec Director
SPONSORED BY The Market Online